EligibleTrials

MMA Embolization for Refractory Chronic Migraine

Recruiting · NCT06735833 · Interventional (participants receive a specific treatment) · Lead sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.

View the official record on ClinicalTrials.gov →
Migraine

Interventions studied

Middle Meningeal Artery embolization

What this trial is about

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Who can take part

Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

7 locations listed across 6 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.